Q-omics provides the consensus-scored MIR7-3HG profile across patient tissues and cancer cell-line models. MIR7-3HG expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, MIR7-3HG is differentially expressed in 7, with the highest sampling consensus in COAD. Additionally, MIR7-3HG RNA expression shows 11,459 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UCEC, COAD, and GBM as cancer lineages where MIR7-3HG shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR7-3HG — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR7-3HG survival associations across molecular data types. MIR7-3HG RNA expression shows survival associations in the most cancer types (20), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR7-3HG RNA expression–survival associations across cancer types. High MIR7-3HG expression shows unfavorable associations in UCEC, KIRC, KICH and THCA, but favorable associations in CESC and ACC. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for MIR7-3HG RNA expression.
This table summarizes MIR7-3HG tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for MIR7-3HG. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR7-3HG shows lower tumor expression in COAD, STAD and READ and higher tumor expression in BRCA, HNSC and KIRC. The COAD box plot shows higher MIR7-3HG RNA expression in normal versus tumor tissue (log2 FC = −0.303, t-test p < 0.001).
This table shows molecular features associated with MIR7-3HG in patient tissues and cancer cell lines. In patient samples, MIR7-3HG shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
